RecruitingPhase 3NCT06665438

Dexmedetomidine and Bupivacaine Intra-articular for Postoperative Analgesia After Knee Arthroscopic Surgery

Impact of Dexmedetomidine Add to Intra-articular Bupivacaine for Post Operative Analgesia After Knee Arthroscopic Surgery


Sponsor

Al-Azhar University

Enrollment

75 participants

Start Date

Dec 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The aim of this study to compare the analgesic effects of intraarticular dexmedetomidine added to bupivacaine with those of bupivacaine alone after knee arthroscopy


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Inclusion Criteria4

  • ASA I-II patients
  • Either sex
  • Aged 18-65 years
  • Candidates for anterior cruciate ligament (ACL) reconstruction by knee arthroscopy

Exclusion Criteria3

  • the patients with kidney failure, liver failure, valvular and ischemic heart disease , high blood pressure, diabetes, history of infection and malignancy.
  • history of coagulation diseases, and history of drug allergies to used drugs.
  • those who consumed NSAIDs and analgesics 24 h before surgery were excluded from the study.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGNormal Saline (Placebo)

the 18 ml of normal saline will injected intra articular in the knee joint by the surgeon through the arthroscope after completing the procedure

DRUGBupivacaine 0.25%

the 18ml 0.25% bupivacaine. will injected intra articular in the knee joint by the surgeon through the arthroscope after completing the procedure

DRUGDexmedetomidine

Dexmedetomidine 1 μg/kg will injected intra articular in the knee joint by the surgeon through the arthroscope after completing the procedure.


Locations(2)

Al-Azhar University

Asyut, Egypt

Al-Azhar University

Asyut, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06665438


Related Trials